



NHS MEDICAL POLICY

Casirivimab and Imdevimab for COVID -19 + Patients Medicine 2021-001

A. May be indicated when ALL the following are present:

1	Administered together for the treatment of mild to moderate COVID-19 patients
2	Given to Adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds])
3	Positive results of direct SARS-Co-V-2 viral testing and who are at high risk for progressing to severe COVID-19.
4	<p>Must have at least one of the following co-morbidities:</p> <ul style="list-style-type: none"> • Cancer • Chronic kidney disease • Chronic lung disease (COPD, asthma [moderate to severe]. Interstitial lung disease, cystic fibrosis, and pulmonary hypertension) • Dementia or other neurological condition • Diabetes (type 1 or type 2) • Down syndrome • Heart conditions (such as heart failure, coronary artery disease, cardiomyopathies, or hypertension) • HIV infection • Immunocompromised state • Liver disease such as alcohol-related liver disease, nonalcoholic fatty liver disease and cirrhosis • Overweight and obesity (BMI >25) • Pregnancy and recently pregnant people (for at least 42 days following end of pregnancy) • Sickle cell disease or thalassemia • Smoking, current or former • Solid organ or blood stem cell transplant • Stroke or cerebrovascular disease • Substance abuse disorders
5	Not hospitalized due to COVID-19

6	Does not require oxygen
---	-------------------------

SOURCES

U. S. Food and Drug Administration Emergency Use Authorization

CODE REFERENCE: (This may not be a comprehensive list of codes to apply to this policy.)

Q0243, Q0244, M0243, M0244

POLICY HISTORY/REVISION INFORMATION

Date	Action/Description
09/19/2022	Annual review and approval by UM Committee
08/23/2023	Annual review and approval by UM/QM Committee
08/23/2024	Annual review and approval by UM/QM Committee